Licensing status

Publication and contact information

Autoimmune disease

Autoimmune disease

RAR-related orphan receptor C
thymus-specific isoform
(RORg2; RORgT)

In vitro and mouse studies suggest RORgT inhibitors could suppress T helper type 17 (Th17) cells to help treat autoimmune diseases. In cultured human Th17 cells, three RORgT inhibitors identified from a small molecule library screen each suppressed production of the proinflammatory cytokine IL-17. In a mouse model of experimental autoimmune encephalomyelitis (EAE), oral GSK805, which was found to inhibit RORgT, or subcutaneous injection of one of the RORgT inhibitors from the screen delayed disease onset and decreased disease severity compared with vehicle. Next steps could include testing the inhibitors in additional autoimmune disease models.
Innovimmune Biotherapeutics Inc. has the RORgT inverse agonist INV-17 in preclinical development for various autoimmune and inflammatory conditions.
GSK805 is an investigational compound to inhibit the HCV NS5A protein that the Janssen Pharmaceutical Inc. unit of Johnson & Johnson acquired from GlaxoSmithKline plc.

SciBX 7(19); doi:10.1038/scibx.2014.549
Published online May 15, 2014

Patent and licensing status unavailable

Xiao, S. et al. Immunity; published online April 17, 2014;
Contact: Vijay K. Kuchroo, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Contact: Alexander Marson, University of California, San Francisco, Calif.